It is well known that α
2 agonists have various pharmacological effects, including sedation, analgesia, and sympatholysis. Since these effects are important in anesthetic management, applying α
2 agonists to clinical anesthesia has been expected. Development of dexmedetomidine, a potent and selective α
2 agonist, facilitated a clinical trial of the drug as an anesthetic adjunct in clinical anesthesia. Unfortunately, this clinical trial was interrupted. However, dexmedetomidine was introduced as a postoperative sedative drug, because it provides high-quality sedation. While we can expect that dexmedetomidine has a lot of potential in clinical anesthesia, we should be careful of side effects because of its various pharmacological actions.
View full abstract